European Medicines Agency (EMA) receives application for conditional authorisation of first COVID-19 treatment in the EU

EMA has now received an application for conditional marketing authorisation of the antiviral medicine remdesivir for the treatment of COVID-19 and has formally started its evaluation. An opinion could be issued within weeks, depending on the robustness of the data submitted.


European Medicines Agency